Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab

Basit Öğe Kaydı
dc.contributor.authorArtac, Mehmet
dc.contributor.authorUysal, Mukremin
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorKorkmaz, Levent
dc.contributor.authorEr, Zehra
dc.contributor.authorGuler, Tunc
dc.contributor.authorBoruban, Melih Cem
dc.date.accessioned2024-02-23T13:59:44Z
dc.date.available2024-02-23T13:59:44Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractPurpose Metastatic colorectal cancer (mCRC) is a lethal disease and fluorouracil-leucovorin-irinotecan (FOLFIRI) plus bevacizumab (bev) is a standard approach. Hence, there is a strong need for identifying new prognostic factors to show the efficacy of FOLFIRI-bev. Methods This is a retrospective study including patients (n = 90) with mCRC from two centers in Turkey. Neutrophil/lymphocyte (N/L) ratio, platelet count, albumin, and Creactive protein (CRP) were recorded before FOLFIRI-bev therapy. The efficacy of these factors on progression-free survival (PFS) was analyzed with Kaplan Meier and Cox regression analysis. And the cutoff value of N/L ratio was analyzed with ROC analysis. Results The median age was 56 years (range 21-80). Forty-seven percent of patients with N/L ratio >2.5 showed progressive disease versus 43 % in patients with N/L ratio <2.5 (p = 0.025). The median PFS was 8.1 months for the patients with N/L ratio >2.5 versus 13.5 months for the patients with N/L ratio <2.5 (p = 0.025). At univariate Cox regression analysis, high baseline neutrophil count, LDH, N/L ratio, and CRP were all significantly associated with poor prognosis. At multivariate Cox regression analysis, CRP was confirmed to be a better independent prognostic factor. CRP variable was divided into above the upper limit of normal (ULN) and normal value. The median PFSs of the patients with normal and above ULN were 11.3 versus 5.8 months, respectively (p = 0.022). Conclusions CRP and N/L ratio are potential predictors for advanced mCRC treated with FOLFIRI-bev.en_US
dc.identifier.doi10.1007/s12029-016-9879-4
dc.identifier.endpage180en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue2en_US
dc.identifier.pmid27714653en_US
dc.identifier.scopus2-s2.0-84990856001en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage176en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-016-9879-4
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11306
dc.identifier.volume48en_US
dc.identifier.wosWOS:000400130200009en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCrpen_US
dc.subjectNeutrophil/Lymphocyte Ratioen_US
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectBevacizumaben_US
dc.subjectSystemic Inflammationen_US
dc.titlePrognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumaben_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu